NICE Rebuffs Reimbursement of AstraZeneca’s COPD Drug Daxas

The UK’s National Institute for Health and Care Excellence did not recommend that the National Health Service reimburse AstraZeneca’s chronic obstructive pulmonary disease therapy Daxas.

In a draft guideline, NICE said that reimbursement of Daxas would not be a cost-effective use of NHS resources based on the therapy’s cost and effectiveness.

The guideline notes there is only some clinical evidence that Daxas reduces the worsening of COPD symptoms, and that the drug’s list price is £113.14 (US $141) per 90 tablets.